SOL Global Investments Past Earnings Performance
Past criteria checks 0/6
SOL Global Investments's earnings have been declining at an average annual rate of -28%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 7.1% per year.
Key information
-28.0%
Earnings growth rate
-29.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -7.1% |
| Return on equity | -442.6% |
| Net Margin | 108.3% |
| Last Earnings Update | 30 Nov 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How SOL Global Investments makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Nov 23 | -32 | -34 | 4 | 0 |
| 31 Aug 23 | -62 | -143 | 11 | 0 |
| 31 May 23 | -67 | -148 | 13 | 0 |
| 28 Feb 23 | -167 | -233 | 17 | 0 |
| 30 Nov 22 | -236 | -297 | 19 | 0 |
| 31 Aug 22 | -226 | -225 | 48 | 0 |
| 31 May 22 | -203 | -275 | 55 | 0 |
| 28 Feb 22 | -20 | -123 | 68 | 0 |
| 30 Nov 21 | 310 | 159 | 69 | 0 |
| 31 Aug 21 | 396 | 260 | 36 | 0 |
| 31 May 21 | 445 | 367 | 32 | 0 |
| 28 Feb 21 | 384 | 303 | 16 | 0 |
| 30 Nov 20 | 139 | 98 | 12 | 0 |
| 30 Nov 19 | -170 | -156 | 8 | 0 |
| 30 Sep 19 | -125 | -151 | 26 | 1 |
| 30 Jun 19 | -85 | 54 | 36 | 2 |
| 31 Mar 19 | -52 | 95 | 35 | 3 |
| 31 Dec 18 | -64 | 83 | 23 | 3 |
| 30 Sep 18 | -17 | 139 | 18 | 3 |
| 30 Jun 18 | 0 | -28 | 15 | 3 |
| 31 Mar 18 | 0 | -26 | 13 | 3 |
| 31 Dec 17 | 0 | -19 | 6 | 3 |
| 30 Sep 17 | 0 | -15 | 3 | 2 |
| 30 Jun 17 | 0 | -3 | 2 | 2 |
| 31 Mar 17 | 0 | -3 | 2 | 1 |
| 31 Dec 16 | 0 | -2 | 2 | 0 |
| 31 Mar 16 | 0 | -3 | 3 | 0 |
Quality Earnings: SOLC.F is currently unprofitable.
Growing Profit Margin: SOLC.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOLC.F is unprofitable, and losses have increased over the past 5 years at a rate of 28% per year.
Accelerating Growth: Unable to compare SOLC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SOLC.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: SOLC.F has a negative Return on Equity (-442.6%), as it is currently unprofitable.